Current data suggest that retatrutide is more robust in fixing metabolic problems than Mounjaro or Ozempic.

For example, its going to greatly decrease heart attacks:

According to Eli Lilly’s results presentation at ESC 2024, retatrutide reduced non-HDL-C by up to 22.2% at 24 weeks and by up to 26.9% at 48 weeks, in a dose-dependent manner; apoB was reduced by up to 19.6% and 24.2% at 24 and 48 weeks, respectively. At 48 weeks, the drug reduced triglycerides and apoC-III levels by up to 40.6% and 38.0%, respectively, and it also reduced the total number of TG-rich lipoprotein particles (TRLP) regardless of their size. Reduction in large and medium TRLP was greater than in small TRLP, therefore the average size of TRLP was smaller following treatment with the drug. Retatrutide also reduced the number of total and highly atherogenic small LDL particles (LDLP), while total and small HDL particles (HDLP) were only slightly reduced. The average size of HDLP increased following treatment with the drug. At 48 weeks, the NMR-derived lipoprotein insulin resistance score was decreased by 27.4%, 31.7%, and 32.5% with the 4mg, 8mg, and 12mg dosages, respectively, following treatment.

It's being studied for NASH, for which there is no FDA approved drug right now:

with obesity or overweight with weight-related complications, treatment for 24 weeks with the GIP/GLP-1/GCG triple receptor agonist, retatrutide, was associated with significant reductions in liver fat content at all doses. At the two highest doses, 80% or more of participants achieved ≥70% relative reduction in liver fat and more than 85% achieved resolution of steatosis, defined as <5% total liver fat content. Near-maximal liver fat reduction was achieved at an approximately 20% reduction in body weight.

https://www.nature.com/articles/s41591-024-03018-2#:~:text=Retatrutide%20is%20a%20novel%20triple,8%20and%2012%20mg%2C%20respectively.

It's being studied for chronic kidney disease as well to see if it slowly progression of chronic kidney disease. No data exists on this as Eli Lilly is enrolling people right now, but here is hte study page.




The good news is that it that it might make Mounjaro significantly less expensive, although Eli Lilly will likely switch production from Mounjaro to retatrutide making it more scarce.